Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Tysabri prescribing information
Neuromyelitis optica.
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Neuromyelitis optica spectrum disorder: 2-deoxy-2-[(18)f]fluoro-d-glucose positron emission tomography findings.
In vitro modeling of central nervous system myelination and remyelination.
Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.
Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial.
Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases.
Visual Functional and Histopathological Correlation in Experimental Autoimmune Optic Neuritis.
Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis.
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Opposing Effects of Membrane-Anchored CX3CL1 on Amyloid and Tau Pathologies via the p38 MAPK Pathway.
Validity and reliability of VO2-max measurements in persons with multiple sclerosis.
Accelerated and enhanced effect of CCR5-transduced bone marrow neural stem cells on autoimmune encephalomyelitis.
Time limited immunomodulatory functions of transplanted neural precursor cells.
Tumefactive multiple sclerosis requiring emergent biopsy and histological investigation to confirm the diagnosis: a case report.
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Amiloride Clinical Trial In Optic Neuritis (ACTION)
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - A twelve month follow-up.

Pages